Search

everythinglearnresearchcommunity

for

Search:↓

YH0618 helps reduce chemotherapy-induced hair loss by targeting specific proteins and pathways.

Deuruxolitinib effectively regrows hair in adults with alopecia areata and is well tolerated.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

Oncology specialists are disappointed by the discontinuation of the effective lymphoma treatment Bexxar.

Effective management of side effects is crucial for safe use of sacituzumab govitecan in advanced breast cancer treatment.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

Pexidartinib often causes liver issues and fatigue, especially in women.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

Targeting vitamin D and androgen receptors may effectively treat triple-negative breast cancer, especially with chemotherapy.

Targeting Keratin 17 may help overcome cancer therapy resistance.

Individualized treatments may help manage Dercum's disease symptoms.

Epirubicin and cyclophosphamide cause more anemia and side effects than docetaxel and cyclophosphamide, but both are equally effective.

A girl with Evans' syndrome had her low platelet count successfully treated with zanubrutinib.

Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.

Combining DEB-BACE with chemotherapy is more effective and has fewer side effects than chemotherapy alone for treating unresectable lung squamous cell carcinoma.

Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

Docetaxel and oxaliplatin are effective and have manageable side effects for recurrent platinum-sensitive ovarian cancer.

AD198 is more effective than doxorubicin in stopping certain dog cancer cells.

Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.

Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.

Patients with metastatic breast cancer treated with epirubicin and docetaxel had a good response and maintained their quality of life.

A man's severe skin reaction from cancer treatment improved with early diagnosis and proper medication.

Deucravacitinib helped a man regrow hair significantly.

Chrysin makes docetaxel more effective and reduces its side effects in lung cancer treatment.

PLD is an effective and safer alternative for treating breast cancer.

EGFR-targeting cancer drugs can cause skin rashes and other side effects.